Small molecule inhibitors of the MLL-menin protein-protein interaction have recently been developed and have been shown to inhibit both oncogenic HOXA gene expression as well as tumor propagation in MLL fusion-driven leukemias [33]. The gene discussed is KMT2A; the disease is neoplasm.